We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Sinclair Pha | LSE:SPH | London | Ordinary Share | GB0033856740 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 31.80 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSPH
RNS Number : 3860L
Sinclair Pharma PLC
30 September 2016
Sinclair Pharma plc
TOTAL ISSUED SHARE CAPITAL
London, 30 September 2016 Sinclair Pharma plc (SPH.L), ("Sinclair" or the "Company"): In accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, Sinclair confirms that the Company's issued share capital consists of 502,089,508 ordinary shares of 1p each in issue, each with equal voting rights. No shares are held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
Sinclair Pharma plc Tel: +44 (0) 20 7467 6920
Chris Spooner
Alan Olby
Andy Crane
Peel Hunt LLP (Nominated Adviser) Tel: +44 (0) 20 7418 8900
James Steel
Oliver Jackson
Notes to Editors:
About Sinclair Pharma plc
Sinclair Pharma plc is an international company operating in the fast growth, high gross margin, global aesthetics market. Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years. Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors. For more information, please visit www.sinclairpharma.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRWGUBPBUPQGWU
(END) Dow Jones Newswires
September 30, 2016 09:29 ET (13:29 GMT)
1 Year Sinclair Pharma Chart |
1 Month Sinclair Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions